紫鑫藥業(002118.SZ):仲維光所持6192.26萬股司法拍賣股份2.1億元成交
格隆匯 12 月 14日丨紫鑫藥業(002118.SZ)公佈,公司近日獲悉,公司控股股東敦化市康平投資有限責任公司(“康平公司”)的一致行動人仲維光因之前合同糾紛案,上海金融法院於2020年12月12日10時至2020年12月13日10時止(延時除外)在“淘寶網”(sf.taobao.com)對仲維光持有公司約6192.26萬股股票進行公開拍賣。
經公開競價,競買人許靜靜通過競買號W9544於2020年12月13日在上海金融法院於阿里拍賣平台開展的“仲某某持有的約6192.26萬股吉林紫鑫藥業股份有限公司無限售流通股票”項目公開競價中,以最高應價勝出。該標的網絡拍賣成交價格約¥2.1億元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.